Highlights

  • Epiminder enrolled the 100th patient in its US DETECT study ahead of its November 2026 target.
  • The clinical programme now has 22 actively enrolling US centres, against a maximum of 25 planned sites.
  • The company anticipates 125 enrolled participants by December 2026.
  • Full enrolment of up to 210 participants remains targeted for the first half of calendar 2027.
  • The announcement reports recruitment progress, not patient outcomes or study efficacy results.

Epiminder Limited (ASX:EPI), which develops continuous brain-monitoring technology for people with epilepsy, has reached a new recruitment milestone in the United States. Its 15 October 2026 announcement confirmed that the DETECT study has enrolled its 100th participant, ahead of the company’s previously stated November target. Recruitment is not proof of clinical benefit.

Recruitment Passes a Planned Checkpoint

Epiminder (ASX:EPI) describes DETECT, short for Diagnosing Epilepsy To EffeCT change, as a prospective, randomised, controlled, blinded, multicentre US study. It evaluates whether the Minder System can improve clinical decision-making for people whose extended electroencephalographic, or EEG, monitoring has produced inconclusive findings. The study is registered as NCT07110337 and is designed to enrol up to 210 participants.

The newly reported cohort represents almost half of that planned maximum. Epiminder (ASX:EPI) also says 22 US centres are actively recruiting, compared with a study network designed to include no more than 25 sites. It does not provide site-by-site enrolment figures.

What the Minder System Is Being Asked to Demonstrate

The Minder System continuously records subscalp EEG information, giving clinicians access to longer-term brain activity data. Epiminder (ASX:EPI) says the device has received US Food and Drug Administration authorisation through the de novo pathway. In DETECT, it is being assessed as a marketed device in a post-market research setting.

Participants have a six-month primary follow-up period. The October update does not disclose patient outcomes, comparative results, specified primary endpoints or the statistical evaluation plan; these cannot be inferred from recruitment figures alone.

Milestones That Frame the Remaining Study

Epiminder (ASX:EPI) expects to have enrolled 125 participants by December 2026 and continues to target completion of enrolment of all 210 patients by the end of the first half of calendar 2027. These dates are forward-looking targets, not completed milestones. The schedule remains subject to recruitment progress.

The six-month follow-up requirement is also important for interpreting the timeline. Completing enrolment does not mean that every participant has completed follow-up, or that analysed results are immediately available. Epiminder has not provided a definite date for the release of full DETECT findings in this announcement.

Commercial Relevance Still Depends on Evidence

Epiminder (ASX:EPI) expects the eventual DETECT findings to inform clinical practice, engagement with healthcare payers and its US commercial approach. The update provides no study-linked sales, reimbursement, pricing or revenue figures. It also does not offer revised financial guidance or a quantified forecast for adoption of the Minder System.

For now, the operational distinction remains clear: faster enrolment may help the company progress its research programme, but clinical effectiveness and subsequent commercial adoption depend on evidence and decisions yet to emerge.

Key Insights

The October 2026 announcement places Epiminder Limited (ASX:EPI) ahead of its stated recruitment schedule, with 100 participants enrolled across 22 active US centres. Its next checkpoints are 125 participants by December and completion of enrolment in the first half of 2027. The principal unanswered issue is whether the eventual controlled study results demonstrate a meaningful effect on clinical decision-making.